Cover Image
Market Research Report
Product code 
271830

High-Grade Glioma - Pipeline Review, H2 2019

Published: | Global Markets Direct | 568 Pages | Delivery time: 1-2 business days

Price

Back to Top
High-Grade Glioma - Pipeline Review, H2 2019
Published: December 27, 2019
Global Markets Direct
Content info: 568 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H2 2019, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated ap-petite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 1, 28, 19, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Unknown stages comprises 3, 2, 3 and 1 molecules, respectively.

High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11738IDB

Table of Contents

  • Introduction
  • High-Grade Glioma - Overview
  • High-Grade Glioma - Therapeutics Development
  • High-Grade Glioma - Therapeutics Assessment
  • High-Grade Glioma - Companies Involved in Therapeutics Development
  • High-Grade Glioma - Drug Profiles
  • High-Grade Glioma - Dormant Projects
  • High-Grade Glioma - Discontinued Products
  • High-Grade Glioma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for High-Grade Glioma, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • High-Grade Glioma - Pipeline by Aadi Bioscience Inc, H2 2019
  • High-Grade Glioma - Pipeline by Advanz Pharmaceutical Corp, H2 2019
  • High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H2 2019
  • High-Grade Glioma - Pipeline by AngioChem Inc, H2 2019
  • High-Grade Glioma - Pipeline by Apollomics Inc, H2 2019
  • High-Grade Glioma - Pipeline by Athenex Inc, H2 2019
  • High-Grade Glioma - Pipeline by Bayer AG, H2 2019
  • High-Grade Glioma - Pipeline by BeiGene Ltd, H2 2019
  • High-Grade Glioma - Pipeline by Berg LLC, H2 2019
  • High-Grade Glioma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2019
  • High-Grade Glioma - Pipeline by Biomimetix JV LLC, H2 2019
  • High-Grade Glioma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • High-Grade Glioma - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • High-Grade Glioma - Pipeline by Cellectar Biosciences Inc, H2 2019
  • High-Grade Glioma - Pipeline by Curis Inc, H2 2019
  • High-Grade Glioma - Pipeline by Curtana Pharmaceuticals Inc, H2 2019
  • High-Grade Glioma - Pipeline by DNAtrix Inc, H2 2019

List of Figures

  • Number of Products under Development for High-Grade Glioma, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019